Genetic Polymorphisms of UGT1A and their Association with Clinical Factors in Healthy Koreans |
Kim, Jeong-Oh
(Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea)
Shin, Jeong-Young (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) Lee, Myung-Ah (Medical Oncology, Kangnam St. Mary's Hospital) Chae, Hyun-Suk (Gastroenterology, Uijeongbu St. Mary's Hospital) Lee, Chul-Ho (Department of Clinical Genetics, School of Medicine, Yonsei University) Roh, Jae-Sook (KFDA, NITR, Team of Clinical Pharmacology) Jin, Sun-Kyung (KFDA, NITR, Team of Clinical Pharmacology) Kang, Tae-Sun (KFDA, NITR, Team of Clinical Pharmacology) Choi, Jung-Ran (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) Kang, Jin-Hyoung (Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea) |
1 | Kiang, T.K., Ensom, M.H., and Chang, T.K. (2005). UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106, 97-132 DOI ScienceOn |
2 | Villeneuve, L., Girard, H., Fortier, L.C., Gagné, J.F., and Guillemette, C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307, 117-128 DOI ScienceOn |
3 | Nowell, S.A., Leakey, J.E., Warren, J.F., Lang, N.P., and Frame, L.T. (1998). Identification of enzymes responsible for the metabolism of heme in human platelets. J. Bio. Chem. 273, 33342-33346 DOI ScienceOn |
4 | Iyer, L., Hall, D., Das, S., Mortell, M.A., Ramirez, J., Kim, S., Di Rienzo, A., and Ratain, M.J. (1999). Phenotypegenotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 DOI ScienceOn |
5 | Innocenti, F., Liu, W., Chen, P., Desai, A.A., Das, S. and Ratain, M.J. (2005). Haplotype of variants in the UDPglucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet. Genomics. 15, 295-301 |
6 | Jada, S.R., Lim, R., Wong, C.I., Shu, X., Lee, S.C., Zhou, Q., Goh, B.C., and Chowbay, B. (2007). Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98, 1461-1467 DOI ScienceOn |
7 | Ahn, C. (2007). Pharmacogenomics in Drug Discovery and Development. Genomics & Informatics. 5(2), 41-45 과학기술학회마을 |
8 | Rhu , H.J., Jung, H.Y., Park, J.S., Kim, J.W., Kim, H.T., Park, C.S., Han, B.G., Koh, I.S., Park, C., Kim, K.h., Oh, B.S., and Lee, J.K. (2005). Genetic variants of IL-3 and IL-4 in the Korean population: Polymorphisms, Haplotypes and Linkage Disequilibrium. Genomics & Informatics. 3(4), 149-153 |
9 | Yamanaka, H., Nakajima, M., Katoh, M., Hara, Y., Tachibana, O., Yamashita, J., McLeod, H.L., and Yokoi, T. (2004). A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 14, 329-32 DOI |
10 | Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., and Hasegawa, Y. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 |
11 | Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, JI., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H., Kubota, K., Yoshida, T., Ohtsu, A., and Saijo, N. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and Genomics. 17, 497-504. DOI |
12 | Mackenzie, P.I., Owens, I.S., Burchell, B., Bock, K.W., Bairoch, A., Bélanger, A., Fournel-Gigleux, S., Green, M., Hum, D.W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Chowdhury, J.R., Ritter, J.K., Schachter, H., Tephly, T.R., Tipton, K.F., and Nebert, D.W. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 7, 255-269 DOI |
13 | Riedy, M., Wang, J.Y., and Miller, A.P. (2000). Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics. 10, 251-260 DOI |
14 | Sandanaraj, E., Jada, S.R., Shu, X., Lim, R., Lee, S.C., Zhou, Q., Zhou, S., Goh, B.D., and Chowbay, B. (2007). Influence of UGT1A9 intronic 1399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J. 1-12 |
15 | Marsh, S., and McLeod, H.L. (2004). Pharmacogenetics of irinotecan toxicity. Pharmacogenetics. 5, 835-843 |
16 | Han, J.Y., Lim, H.S., Shin, E.S., Yoo, Y.K., Park, Y.H., Lee, J.E., Jang, I.J., Lee, D.H., and Lee, J.S. (2006). Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 DOI ScienceOn |
17 | Innocenti, F., Grimsley, C., Das, S., Ramírez, J., Cheng, C., Kuttab-Boulos, H., Ratain, M.J., and Di Rienzo, A. (2002). Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 12, 725-733 DOI |